Johnson & Johnson submits sNDA for SPRAVATO to treat depression
The sNDA filing is based on the positive outcomes of the Phase IV TRD4005 study.
mental health conditions
Enveric Biosciences to out-license psilocin prodrug to MindBio
Clearmind licenses psychedelic compounds for mental disorders
Enveric’s EB-003 selected as lead candidate for mental health disorders
Waning focus on abuse potential may negatively affect pipeline non-stimulants for ADHD
Gate Neurosciences plans Phase II MDD trial with next-gen antidepressant
FDA grants Fast-Track status for Relmada’s major depressive disorder therapy
Alto Neuroscience uses AI to create biomarkers for personalised mental health drugs
